Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial
- 28 April 2000
- journal article
- clinical trial
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 10 (3), 211-217
- https://doi.org/10.1016/s0924-977x(00)00074-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Somatoform Disorders - Diagnostic Concept, Controlled Clinical Trials, and Methodological IssuesPharmacopsychiatry, 1994
- Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder?Pain, 1991
- The Bradford Somatic InventoryThe British Journal of Psychiatry, 1991
- Blockade of hippocampal dopamine (da) receptors: A tool for antipsychotics with low extrapyramidal side effectsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1988
- The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disordersJournal of Affective Disorders, 1988
- Somatization in the community: relationship to disability and use of services.American Journal of Public Health, 1987
- Detection of dopamine receptors in homogenates of rat hippocampus and other brain areasBrain Research, 1986
- The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptorsEuropean Journal of Pharmacology, 1986
- Opipramol in the climacteric syndrome. A double-blind, placebo-controlled trialMaturitas, 1983
- In vivo [3H]spiperone binding to the rat hippocampal formation: Involvement of dopamine receptorsEuropean Journal of Pharmacology, 1980